WICK VapoRub launches New Applicator for Targeted Relief
Schwalbach, Germany - WICK pharma, a branch of Procter & Gamble GmbH, has introduced a new VapoRub formulation featuring a convenient applicator, designed for easier and more precise submission, eliminating messy hands. The over-the-counter product remains indicated for symptomatic relief of colds and acute pneumonia in infants and young children – specifically, under 2 years old – and children under 6 years old, excluding inhalation use.
The updated delivery method addresses a common consumer concern regarding the conventional ointment’s application. While VapoRub has long been a household staple, the new applicator aims to improve user experience and ensure targeted treatment. However, consumers should remain aware of potential side effects, which include skin hypersensitivity reactions, contact dermatitis, and, in rare cases, hallucinations or seizures. Inhalation of the product can cause irritation, coughing, worsening bronchospasm, airway obstruction, and potentially respiratory arrest.Burns at the application site are also possible.
WICK Pharma, part of P&G’s healthcare division, markets a portfolio of brands including Femibion, Clearblue, Oral-B, Bion3, and Vigantol/Vigantolvit. P&G’s healthcare business generates over $7.5 billion in net sales globally, operating across North America, Latin America, Western Europe, CEE, Asia, India, Middle East, Africa, and Australia, with a workforce exceeding 3,500 employees. The new WICK VapoRub applicator was released in March 2018 and is available for purchase now.
